Coronary CT calcium scan

The Lundquist Institute Receives $1.5 Million Gift from Farima and Joseph Czyzyk to Make Life-Saving Technology Accessible to the Public

Retrieved on: 
Tuesday, October 25, 2022
UCLA, Coronary CT calcium scan, Doctor of Philosophy, Cancer, CAC, Health, CEO, Harbor–UCLA Medical Center, CT, Risk, David Geffen School of Medicine at UCLA, Wellness, Infection, Moyamoya disease, Institute of Health and Biomedical Innovation, Division, Patient, Technology, CT scan, Education, John F. Cotton Corporate Wellness Center, Research, GLOBE, Program director, Heart, Atherosclerosis, Degenerative disease, Pharmaceutical industry, Medical device, Medical imaging, Medicine, Cardiology

In recognition of this generous gift, the Institutes Diagnostic and Wellness Center will be renamed the Farima Czyzyk Center for Cardiac Research and Wellness.

Key Points: 
  • In recognition of this generous gift, the Institutes Diagnostic and Wellness Center will be renamed the Farima Czyzyk Center for Cardiac Research and Wellness.
  • As a patient, I have benefited from this screening technology at Harbor-UCLA, said Farima Czyzyk, adding, and I am very impressed with Dr. Budoffs work and mission.
  • Czyzyk also said that those who lack the means too often forego critical preventative care that could ultimately save or extend their lives.
  • We appreciate this vote of confidence through the establishment of The Farima Czyzyk Center for Cardiac Research and Wellness.

Zebra Medical Vision Secures 8th FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

Retrieved on: 
Monday, September 27, 2021
Other Health, Software, Managed Care, Data Management, Medical Devices, Technology, Hospitals, Cardiology, Biotechnology, Other Technology, FDA, Health, Adoption, Mortality, Coronary CT calcium scan, Insurance, Solution, Health, Internationalized domain name, CT, NASDAQ, Radiation exposure, FDA, Multimedia, Patient, CAC, Population, Physician, Cardiovascular disease, Zebra, CEO, Gaps, Disease, CVD, Risk, Conditional sentence, Radiology, Cardiology, Medical device, Pharmaceutical industry, Medical imaging

Zebra Medical Vision , the deep-learning medical imaging analytics company, announces today its eighth FDA 510(k) clearance for its cardiac solution, "HealthCCSng" which has already received a CE mark.

Key Points: 
  • Zebra Medical Vision , the deep-learning medical imaging analytics company, announces today its eighth FDA 510(k) clearance for its cardiac solution, "HealthCCSng" which has already received a CE mark.
  • View the full release here: https://www.businesswire.com/news/home/20210927005367/en/
    Zebra Medical Vision secures 8th FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering (Photo: Zebra-Med)
    Approximately 90% of the annual $3.5 Trillion healthcare spending is allocated towards chronic disease management.
  • The company remains firmly committed to its robust product roadmap, which is designed to advance population health and preventative care.
  • Zebra Medical Visions solutions integrate into existing radiology workflows, including primary care physicians and specialists in cardiology, bone health and others.

National Lipid Association Releases Official Scientific Statement on Coronary Artery Calcium Scoring for ASCVD Risk Reduction

Retrieved on: 
Saturday, December 12, 2020
Circulatory system, Cardiovascular system, Medical specialties, Cardiology, Cardiovascular diseases, Cardiac imaging, Coronary CT calcium scan, Coronary artery disease, Atherosclerosis, Cardiovascular disease, Statin, TIMI

JACKSONVILLE, Fla., Dec. 12, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on coronary artery calcium (CAC) scoring for atherosclerotic cardiovascular disease (ASCVD) risk reduction.

Key Points: 
  • JACKSONVILLE, Fla., Dec. 12, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on coronary artery calcium (CAC) scoring for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
  • The statement provides updates on the evidence-based appropriate use of CAC scoring and makes practical recommendations to aid clinicians in primary prevention treatment decision-making in contemporary clinical practice.
  • Coronary calcium scoring is the best available non-invasive marker of cardiovascular risk, Stated the corresponding author, Carl E. Orringer, MD, Associate Professor Medicine at the University of Miami, Miller School of Medicine, Cardiovascular Division.
  • The statement delves into CAC scoring for ASCVD risk prediction; optimal timing for repeat CAC scoring; use of CAC scoring in those taking statins; and its role in informing the clinician-patient discussion on the benefit of aspirin and anti-hypertensive drug therapy.

Genetesis Pilot study: 90-second scan shows promise in evaluating chest pain patients in Emergency Department observation unit

Retrieved on: 
Thursday, January 30, 2020
Circulatory system, Cardiovascular system, RTT, Medicine, Aging-associated diseases, Pain, Torso, Medical emergencies, Coronary artery disease, Chest pain, Coronary CT calcium scan, Heart

Emergency physicians must rapidly identify patients whose chest pain is cardiac-related.

Key Points: 
  • Emergency physicians must rapidly identify patients whose chest pain is cardiac-related.
  • A new pilot study has found that a resting 90-second magnetocardiography (MCG) scan shows promise in evaluating emergency department observation unit (EDOU) chest pain patients for Acute Coronary Artery Syndrome.
  • The study titled "A 90-second Magnetocardiogram Using a Novel Analysis System to Assess for Coronary Artery Stenosis in Emergency Department Observation Unit Chest Pain Patients" was published online by the International Journal of Cardiology Heart and Vasculature on January 8th, 2020.
  • In the prospective emergency department observation unit clinical study, 101 low-intermediate risk chest pain patients were administered a 90-second noninvasive heart scan using the CardioFlux MCG.

AI Helps Find Signs of Heart Disease on Lung Cancer Screens

Retrieved on: 
Tuesday, December 3, 2019
Medicine, RTT, Circulatory system, Medical specialties, Cardiac imaging, Cardiology, Coronary CT calcium scan, Statin, CT scan, Cardiovascular disease, Lung cancer screening, Coronary arteries

Low-dose chest CT is approved for lung cancer screening in high-risk people, such as long-time smokers.

Key Points: 
  • Low-dose chest CT is approved for lung cancer screening in high-risk people, such as long-time smokers.
  • While these CT scans are intended to diagnose lung cancer, coronary artery calcium, a measure of plaque in the arteries, is also visible on CT.
  • The coronary artery calcium score derived from CT is a well-established measure that helps doctors decide who should get cholesterol-lowering preventive medications called statins.
  • "For select patients at intermediate risk of heart disease, if the calcium score is 0, statin can be deferred.

Sanifit announces that Phase 2b CaLIPSO trial of SNF472 met its primary endpoint

Retrieved on: 
Wednesday, October 30, 2019
Anatomy, RTT, Kidney diseases, Cardiac imaging, Cardiology, Coronary CT calcium scan, Chronic kidney disease, Branches of biology

Palma, Spain and San Diego, USA, 30 October 2019 Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint.

Key Points: 
  • Palma, Spain and San Diego, USA, 30 October 2019 Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint.
  • The study demonstrated a reduction in coronary artery calcium (CAC) volume in patients treated with SNF472 as compared to patients receiving placebo over a 52-week period.
  • The CaLIPSO Study is a 52-week, double-blind, randomized, placebo-controlled trialevaluating the effects of 300mg and 600mg of SNF472 on the progression of cardiovascular calcification (CVC) assessed by the CAC score and other assessments by computed tomography (CT).
  • The study was conducted at 65 investigational sites in the US, Spain and the UK.

SHAPE Doctors Urge People to Consider Coronary Calcium Score Before Stopping Aspirin

Retrieved on: 
Tuesday, March 26, 2019
Branches of biology, Medicine, Clinical medicine, Medical tests, CT scan, Multidimensional signal processing, Cardiac imaging, Calcium in biology, Coronary CT calcium scan, Coronary artery disease

"Hospitals do not need new diagnostic technologies to offer coronary calcium scoring, almost all of them have access to a CT scanner, which is all they need."

Key Points: 
  • "Hospitals do not need new diagnostic technologies to offer coronary calcium scoring, almost all of them have access to a CT scanner, which is all they need."
  • "It is great that coronary calcium scoring moved up in the new guideline.
  • Many practicing physicians are still unaware of the value of coronary calcium scoring and have not yet incorporated it into their practice.
  • The good news is that the cost of coronary calcium scoring has decreased significantly from what it was over a decade ago.

SHAPE President Welcomes Addition of Coronary Calcium Scanning to New AHA/ACC Heart Disease Prevention Guidelines Calls It "A Long Time Coming"

Retrieved on: 
Monday, November 19, 2018
RTT, Medicine, Circulatory system, Clinical medicine, Steven Nissen, Myocardial infarction, Heart, Cardiovascular disease, Cardiology, Coronary artery disease, Coronary CT calcium scan

Additionally, the SHAPE organization called out Dr. Steven Nissen for misrepresentation on the cost of coronary calcium testing in his interview with CNN.

Key Points: 
  • Additionally, the SHAPE organization called out Dr. Steven Nissen for misrepresentation on the cost of coronary calcium testing in his interview with CNN.
  • One of the major advancements in the new guideline is the addition of coronary calcium scoring to personalize risk assessment and drug therapy.
  • CAC is a measure of the amount of plaque in the coronary arteriesthe source of heart attacks.
  • "The American Heart Association and American College of Cardiology represent the best of the best in the fight against heart disease.